Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Intuitive Surgical Inc Stock Research

ISRG

291.43USD+0.69(+0.24%)Market Closed
Watchlist

Market Summary

USD291.43+0.69
Market Closed
0.24%

ISRG Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)

ISRG Stock Price

ISRG RSI Chart

ISRG Valuation

Market Cap

102.4B

Price/Earnings (Trailing)

71.85

Price/Sales (Trailing)

15.36

EV/EBITDA

57.58

Price/Free Cashflow

55.1

ISRG Price/Sales (Trailing)

ISRG Profitability

EBT Margin

25.29%

Return on Equity

11.7%

Return on Assets

10.05%

Free Cashflow Yield

1.82%

ISRG Fundamentals

ISRG Revenue

Revenue (TTM)

6.7B

Revenue Y/Y

15.36%

Revenue Q/Q

3.52%

ISRG Earnings

Earnings (TTM)

1.4B

Earnings Y/Y

36.71%

Earnings Q/Q

18.44%

Price Action

52 Week Range

180.07358.07
(Low)(High)

Last 7 days

-3.0%

Last 30 days

-2.3%

Last 90 days

-12.7%

Trailing 12 Months

54.7%

ISRG Financial Health

Current Ratio

5.26

ISRG Investor Care

Buy Backs (1Y)

1.90%

Diluted EPS (TTM)

3.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ISRG

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-14
Ladd Amy L
sold
-152,840
305
-500
-
2023-08-07
LEVY ALAN J
sold
-620,000
310
-2,000
-
2023-08-07
LEVY ALAN J
acquired
172,074
86.0371
2,000
-
2023-07-31
GUTHART GARY S
sold
-808,207
325
-2,480
ceo
2023-07-28
GUTHART GARY S
gifted
-
-
-16,000
ceo
2023-07-28
GUTHART GARY S
sold
-16,440,700
326
-50,314
ceo
2023-07-28
GUTHART GARY S
acquired
2,877,980
42.6367
67,500
ceo
2023-07-25
DeSantis Robert
sold
-732,315
323
-2,265
evp & chief strategy & corp op
2023-07-25
DeSantis Robert
acquired
590,185
232
2,535
evp & chief strategy & corp op

1–10 of 50

Which funds bought or sold ISRG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
reduced
-18.96
2,220,940
28,437,800
0.11%
2023-09-26
M Holdings Securities, Inc.
sold off
-100
-575,000
-
-%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
4,835
19,118
-%
2023-09-20
BARCLAYS PLC
added
183
347,307,000
471,619,000
0.30%
2023-09-12
Farther Finance Advisors, LLC
reduced
-1.99
23,976
100,872
0.02%
2023-09-12
Prosperity Financial Group, Inc.
new
-
237,990
237,990
0.21%
2023-09-12
Prosperity Wealth Management, Inc.
new
-
371,005
371,005
0.24%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
reduced
-16.67
177
1,710
-%
2023-09-07
Strategic Financial Concepts, LLC
added
0.47
75,473
294,410
0.11%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
reduced
-1.91
7,082,950
29,720,400
3.44%

1–10 of 47

Latest Funds Activity

Are funds buying ISRG calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ISRG
No. of Funds

Schedule 13G FIlings of Intuitive Surgical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
5.9%
20,823,995
SC 13G/A
Feb 09, 2023
vanguard group inc
8.33%
29,425,186
SC 13G/A
Feb 03, 2023
blackrock inc.
8.0%
28,447,145
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
6.9%
24,756,021
SC 13G/A
Feb 07, 2022
blackrock inc.
7.4%
26,538,660
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
8.1%
9,599,898
SC 13G/A
Feb 10, 2021
vanguard group inc
7.76%
9,127,891
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G/A
Jan 29, 2021
blackrock inc.
7.6%
8,888,304
SC 13G/A
Feb 14, 2020
price t rowe associates inc /md/
8.9%
10,347,449
SC 13G/A

Recent SEC filings of Intuitive Surgical

View All Filings
Date Filed Form Type Document
Sep 15, 2023
4
Insider Trading
Sep 14, 2023
144
Notice of Insider Sale Intent
Aug 29, 2023
144
Notice of Insider Sale Intent
Aug 14, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading

Peers (Alternatives to Intuitive Surgical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.1B
31.6B
-3.94% -2.93%
28.69
3.3
1.57% -30.40%
102.4B
6.7B
-2.29% 54.71%
71.85
15.36
11.75% -0.66%
101.2B
19.5B
-1.64% 35.04%
37.36
5.2
10.36% 30.30%
71.3B
19.0B
-6.81% 13.51%
44.09
3.79
0.46% -5.24%
42.6B
5.7B
-7.61% -15.82%
30.67
7.53
5.64% -4.53%
MID-CAP
9.2B
937.8M
-2.31% 34.57%
316.65
9.84
16.30% 250.21%
7.3B
616.6M
-8.54% -23.02%
30.01
11.87
69.52% 343.68%
5.0B
1.1B
-9.61% -15.17%
23.85
4.57
12.63% 50.85%
2.8B
452.1M
-18.56% -28.66%
-28.09
6.17
24.99% 24.09%
1.4B
790.3M
-22.43% -53.70%
-6.03
1.71
3.21% -1604.53%
SMALL-CAP
955.9M
780.7M
-5.52% -6.22%
-26.55
1.22
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
610.4M
162.2M
25.64% -36.45%
-7.26
3.76
9.71% 12.37%
590.7M
162.9M
-22.30% -62.37%
-11.17
3.63
42.67% 12.82%

Intuitive Surgical News

InvestorsObserver
Should You Add Intuitive Surgical, Inc. (ISRG) Stock to Your Portfolio Wednesday?.
InvestorsObserver,
6 hours ago
Best Stocks
The Motley Fool
Investor's Business Daily
The Motley Fool

Returns for ISRG

Cumulative Returns on ISRG

21.7%


10-Year Cumulative Returns

20.2%


7-Year Cumulative Returns

8.9%


5-Year Cumulative Returns

9.0%


3-Year Cumulative Returns

Risks for ISRG

What is the probability of a big loss on ISRG?

76.2%


Probability that Intuitive Surgical stock will be more than 20% underwater in next one year

38.1%


Probability that Intuitive Surgical stock will be more than 30% underwater in next one year.

17.3%


Probability that Intuitive Surgical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ISRG drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Intuitive Surgical was unfortunately bought at previous high price.

Drawdowns

Financials for Intuitive Surgical

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue3.6%6,6656,4316,2226,1185,9645,9065,7105,4895,1634,5514,3584,3074,3584,6044,4794,2474,0403,8503,7243,5703,457
Cost Of Revenue---------------------1,029
Gross Profit3.5%4,4484,2994,1964,1464,0654,0663,9593,7943,5463,0262,8612,8612,9233,1793,1102,9502,8072,6802,6042,5022,428
Operating Expenses3.0%2,8262,7432,6192,4912,3672,2532,1382,0071,9321,8421,8111,8301,7961,7741,7361,6411,5501,5051,4051,3061,265
  S&GA Expenses2.5%1,8751,8291,7401,6731,6001,5321,4671,3701,3051,2341,2161,2281,2131,2131,1781,1201,0581,038987921903
  R&D Expenses4.1%951913879818767722671637627608595602583560557521492467418385361
EBITDA-100.0%-1,6261,6071,6661,7252,1242,1702,1432,0181,3481,2071,2021,2461,5311,5021,4291,3661,269---
EBITDA Margin-100.0%-0.25*0.26*0.27*0.34*0.36*0.38*0.39*0.39*0.30*0.28*0.28*0.29*0.33*0.34*0.34*0.34*0.33*---
Earnings Before Taxes5.7%1,7191,6261,6071,6661,7251,8441,8901,8731,7671,3481,2071,2021,2461,5311,5021,4291,3661,2691,2801,2621,218
EBT Margin-100.0%-0.25*0.26*0.27*0.34*0.31*0.33*0.34*0.34*0.30*0.28*0.28*0.29*0.33*0.34*0.34*0.34*0.33*---
Net Income8.6%1,4251,3121,3221,3781,4351,6441,7051,6891,6231,1731,0611,0531,1361,3861,3791,3141,2101,1471,128804810
Net Income Margin-100.0%-0.20*0.21*0.23*0.29*0.28*0.30*0.31*0.31*0.26*0.24*0.24*0.26*0.30*0.31*0.31*0.30*0.30*---
Free Cashflow-100.0%-1,6391,4911,6211,7391,8352,0892,1491,9221,6101,4851,4101,5321,6181,5981,3841,3071,223---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets6.5%13,90313,05312,97413,26113,70513,67813,55512,93512,29711,54011,16910,61810,1049,8919,7339,1318,5328,2357,8477,3196,850
  Current Assets16.8%8,0326,8776,2536,2936,2935,8035,8455,7286,0176,0666,6266,3005,8994,6924,6634,3174,0724,0254,3334,2533,986
    Cash Equivalents60.3%3,4352,1431,5811,5381,5511,1181,3061,3621,6311,4181,6391,3862,0521,2391,1839858058919091,0231,219
  Inventory6.2%1,005947893837724653587585570577602663646620596580513468409370332
  Net PPE9.7%2,8312,5802,3742,2442,1091,9681,8761,7381,6511,5931,5771,5101,4501,3691,2731,1371,032935812746689
  Goodwill0%3493493493483493433443443443453373363373353073052452486.00236211
Liabilities10.5%1,9441,7591,8611,6871,6231,5221,6041,4751,4181,3501,4101,3311,3371,3611,4491,3541,2521,1951,1591,030980
  Current Liabilities17.7%1,5381,3071,4221,2331,1751,1121,1501,0271,0059059658959259461,030931808740821703666
Shareholder's Equity5.2%11,87911,29411,04211,51512,08212,15711,95211,46010,88010,1909,7599,2878,7668,5318,2857,7777,2807,0406,6886,2895,869
  Retained Earnings12.1%3,8083,3973,5004,0184,6834,8584,7614,3904,0233,5153,2612,9372,6332,5712,4952,1431,8191,6961,5221,234948
  Additional Paid-In Capital2.8%8,1517,9287,7047,6857,4847,3557,1647,0156,8046,6276,4456,3046,0855,9275,7575,6015,4305,3295,1705,0634,929
Accumulated Depreciation---1,238---969---758---563---436--
Shares Outstanding0.3%351350350353358358358357356354353352350349348346346345344342341
Minority Interest5.4%81.0077.0071.0059.0059.0055.0050.0049.0042.0037.0028.0029.0026.0024.0021.0016.0014.0016.009.008.009.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations13.4%1,8581,6391,4911,6211,7391,8352,0892,1491,9221,6101,4851,4101,5321,6181,5981,3841,3071,2231,1701,1641,198
  Share Based Compensation3.7%552532513503485467449435420408395382365350336317298280261246232
Cashflow From Investing4.2%2,2502,1591,371155-1,228-2,079-2,461-2,154-2,341-1,420-940-1,012-203-962-1,154-1,234-1,590-1,412-1,049-879-566
Cashflow From Financing19.8%-2,208-2,753-2,572-1,590-595-54.7043.00-15.402.00-9.20-85.705.00-79.10-305-168-185-12993.00126-150-124
  Buy Backs-17.5%2,3512,8512,6071,607607107-34.0034.0034.00134100170370270270200--274274

ISRG Income Statement

2023-06-30
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 1,755.9$ 1,522.1$ 3,452.1$ 3,009.8
Cost of revenue:    
Total cost of revenue584.0498.81,167.2976.8
Gross profit1,171.91,023.32,284.92,033.0
Operating expenses:    
Selling, general and administrative464.3418.4944.8809.5
Research and development244.4207.3489.3417.8
Total operating expenses708.7625.71,434.11,227.3
Income from operations463.2397.6850.8805.7
Interest and other income, net36.09.370.23.6
Income before taxes499.2406.9921.0809.3
Income tax expense73.293.3134.2126.3
Net income426.0313.6786.8683.0
Less: net income attributable to noncontrolling interest in joint venture5.25.810.79.6
Net income attributable to Intuitive Surgical, Inc.$ 420.8$ 307.8$ 776.1$ 673.4
Net income per share attributable to Intuitive Surgical, Inc.:    
Basic (in dollars per share)$ 1.20$ 0.86$ 2.21$ 1.88
Diluted (in dollars per share)$ 1.18$ 0.85$ 2.18$ 1.84
Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:    
Basic (in shares)350.9358.1350.6358.2
Diluted (in shares)357.3363.9356.6365.3
Other comprehensive income (loss), net of tax:    
Unrealized gains on hedge instruments$ 6.0$ 4.4$ 8.5$ 5.4
Unrealized gains (losses) on available-for-sale securities13.1(33.4)50.7(124.1)
Foreign currency translation gains (losses)8.5(5.5)22.7(2.0)
Prior service cost for employee benefit plans0.00.00.00.1
Other comprehensive income (loss)27.6(34.5)81.9(120.6)
Total comprehensive income453.6279.1868.7562.4
Less: comprehensive income attributable to noncontrolling interest4.14.89.99.0
Total comprehensive income attributable to Intuitive Surgical, Inc.449.5274.3858.8553.4
Corporate Joint Venture    
Operating expenses:    
Less: net income attributable to noncontrolling interest in joint venture5.25.810.79.6
Product    
Revenue:    
Total revenue1,468.61,270.42,881.62,508.8
Cost of revenue:    
Total cost of revenue498.0421.0991.0818.3
Service    
Revenue:    
Total revenue287.3251.7570.5501.0
Cost of revenue:    
Total cost of revenue$ 86.0$ 77.8$ 176.2$ 158.5

ISRG Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 3,435.4$ 1,581.2
Short-term investments2,363.82,536.7
Accounts receivable, net904.2942.1
Inventory1,005.2893.2
Prepaids and other current assets323.2299.8
Total current assets8,031.86,253.0
Property, plant, and equipment, net2,830.82,374.2
Long-term investments1,332.52,623.6
Deferred tax assets666.5664.6
Intangible and other assets, net693.1710.1
Goodwill348.6348.5
Total assets13,903.312,974.0
Current liabilities:  
Accounts payable199.7147.0
Accrued compensation and employee benefits346.6401.6
Deferred revenue405.2397.3
Other accrued liabilities586.9476.2
Total current liabilities1,538.41,422.1
Other long-term liabilities405.2439.3
Total liabilities1,943.61,861.4
Contingencies (Note 8)
Stockholders’ equity:  
Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; zero shares issued and outstanding as of June 30, 2023, and December 31, 20220.00.0
Common stock, 600.0 shares authorized, $0.001 par value, 351.3 shares and 350.0 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively0.40.4
Additional paid-in capital8,150.87,703.9
Retained earnings3,807.73,500.1
Accumulated other comprehensive loss(79.8)(162.5)
Total Intuitive Surgical, Inc. stockholders’ equity11,879.111,041.9
Noncontrolling interest in joint venture80.670.7
Total stockholders’ equity11,959.711,112.6
Total liabilities and stockholders’ equity$ 13,903.3$ 12,974.0
Gary S. Guthart
9790
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.